Sugi Predict

Sugi Predict / Compounds / SCHEMBL657377

SCHEMBL657377

SCHEMBL657377

CC1CN([C@H]2C[C@H](O)[C@@H](CO)O2)C(=O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ TK1 P04183 3/20 0.43
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ADRB1 P08588 1/20 0.43
▸ DNMT1 P26358 1/20 0.43
▸ TK2 O00142 1/20 0.43
▸ ALOX12 P18054 1/20 0.41
▸ ADRA1A P35348 1/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ TSHR P16473 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ PMP22 Q01453 1/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL657378 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL16180381 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL15895622 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL15893331 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL11780860 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL24254562 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL15893328 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL16180380 1.00 TK1 (0.43) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL9153935 0.91 TK1 (0.38) TK1LMNASMN1; SMN2ADRB1DNMT1
SCHEMBL9443827 0.88 TK1 (0.36) TK1LMNASMN1; SMN2ADRB1DNMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 181 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025024123-A1 NOVEL CITICOLINE DERIVATIVES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-01-30 — — WO claimed
CN-110612119-A Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents 西雅图儿童医院（DBA西雅图儿童研究所） 2019-12-24 — — CN claimed
WO-2018148224-A1 PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2018-08-16 — — WO claimed
US-20160082133-A1 CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-24 — — US claimed
WO-2014172359-A1 CHEMICAL EXCHANGE SATURATION TRANSFER (CEST) BASED MRI USING REPORTER GENES AND SUBSTRATES AND METHODS THEREOF THE JOHNS HOPKINS UNIVERSITY (US) 2014-10-23 — — WO claimed
US-20130337048-A1 METHOD AND COMPOSITIONS FOR TREATING HIV INFECTION Children's Research Institute, Children's National Medical Center 2013-12-19 — — US claimed
US-20100183707-A1 METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION Children's Research Institute, Children's National Medical Center (US) 2010-07-22 — — US claimed
CN-1826129-A Methods and compositions relating to isoleucine boroproline compounds POINT THERAPEUTICS INC (US) 2006-08-30 — — CN claimed
EP-1485395-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS Biota, Inc. (US) 2004-12-15 — — EP claimed
WO-2003072757-A9 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA INC (US) 2004-10-21 — — WO claimed
WO-2003072757-A2 NUCLEOTIDE MIMICS AND THEIR PRODRUGS BIOTA, INC. (US) 2003-09-04 — — WO claimed
EP-0626970-A1 DIHYDROPYRIMIDINE NUCLEOSIDES WITH ANTIVIRAL PROPERTIES THE UNIVERSITY OF ALBERTA (CA) 1994-12-07 — — EP claimed
WO-1994014831-A1 DIHYDROPYRIMIDINE NUCLEOSIDES WITH ANTIVIRAL PROPERTIES THE UNIVERSITY OF ALBERTA (CA) 1994-07-07 — — WO claimed
US-12584168-B2 Sample preparation method OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2026-03-24 — — US disclosed
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS OPENTRONS LABWORKS INC (US) 2026-03-05 — — US disclosed
US-20250313889-A1 SAMPLE PREPARATION METHOD OXFORD NANOPORE TECHNOLOGIES PLC (GB) 2025-10-09 — — US disclosed
WO-1990001492-A1 METHOD OF PREPARATION OF 2',3'-DIDEOXYNUCLEOSIDES UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 1990-02-22 — — WO disclosed
WO-1990000555-A1 LIPID DERIVATIVES OF ANTIVIRAL NUCLEOSIDES, LIPOSOMAL INCORPORATION AND METHOD OF USE VICAL, INC. (US) 1990-01-25 — — WO disclosed
EP-0350287-A2 Lipid derivatives of antiviral nucleosides, liposomal incorporation and method of use NeXstar Pharmaceuticals, Inc. (US) 1990-01-10 — — EP disclosed
EP-0273277-A2 Pharmaceutical composition comprising 3'-deoxythymidin-2'-ene (3'-deoxy-2',3'-didehydrothymidine) in treating patients infected with retrovirus YALE UNIVERSITY (US) 1988-07-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12584168-B2 Sample preparation method POLN, POLRMT, POLM TK1 472/4885LMNA 171/4885SMN1; SMN2 611/4885
US-20260066042-A1 METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS POLRMT, POLL, SARS1 TK1 1713/4885LMNA 3119/4885SMN1; SMN2 3068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.